Nkengasong was a founding leader of PEPFAR and has served on IAVI’s board since 2018.
Janssen-sponsored trial in sub-Saharan Africa discontinued due to lack of efficacy.
New leadership program positions homegrown scientists to drive research into HIV and other infectious diseases in Africa and India.
Vaccine candidate targets vulnerabilities common across many HIV-1 variants.
A Q&A with Dr. Gagandeep Kang, professor of microbiology at the Wellcome Trust Research Laboratory, held on May 12, 2021, and co-organized by IAVI...
A commentary by Mark Feinberg, M.D., Ph.D., IAVI president and CEO
IAVI’s Dr. Jayanta Bhattacharya, of the Translational Health Science and Technology Institute, India, is interviewed by DBT/Wellcome Trust India All...
IAVI remembers Dr. Deepak Gaur, Deputy Country Director, India, and extends our deepest sympathies to his family.
This HIV Vaccine Awareness Day, we join the call for women to be at the center of the HIV response to lead their own solutions.
Scientists and community liaisons highlight the importance of collaboration in achieving an affordable, globally accessible HIV vaccine.
A spate of news coverage on the results of the Phase I IAVI G001 HIV vaccine clinical trial reflects current public interest in vaccine development ...